Pietro Bulian Selected Research

Pietro Bulian Research Topics

17	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2022 - 03/2006
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2012 - 01/2008
2	Lymphoma (Lymphomas) 12/2017 - 01/2016
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2019
1	Neoplasms (Cancer) 01/2018
1	Lymphocytosis 01/2018
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2017
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2016
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2016
1	Residual Neoplasm 10/2014
1	Pathologic Complete Response 10/2014
1	Corneal Neovascularization 04/2013
1	Headache (Headaches) 03/2010
1	Meningitis 03/2010
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2010
1	Anemia 04/2004
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 04/2004

4	Rituximab (Mabthera)FDA Link 01/2016 - 02/2012
4	Biological ProductsIBA 02/2012 - 01/2008
3	ibrutinibIBA 05/2022 - 01/2018
3	fludarabineIBA 10/2015 - 02/2012
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2012 - 07/2006
3	Surface Antigens (Surface Antigen)IBA 01/2011 - 03/2006
3	Proteins (Proteins, Gene)FDA Link 01/2010 - 07/2006
2	ChemokinesIBA 01/2018 - 05/2009
2	IntegrinsIBA 01/2018 - 01/2016
1	serum P-component (CIt)IBA 10/2021
1	Integrin alpha4beta1 (VLA-4)IBA 01/2018
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2018
1	3' Untranslated Regions (3' UTR)IBA 01/2017
1	Antiviral Agents (Antivirals)IBA 01/2016
1	Natalizumab (Tysabri)FDA Link 01/2016
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2015
1	Proteoglycans (Proteoglycan)IBA 04/2013
1	Cytarabine (Cytosar-U)FDA LinkGeneric 03/2010
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 05/2009
1	Integrin alpha4IBA 01/2008
1	Immunoglobulins (Immunoglobulin)IBA 01/2008
1	Hemoglobins (Hemoglobin)IBA 04/2004